Back to results
US 2011/0213219 A1Published application
Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression
AssigneeRidge Diagnostics, Inc.
InventorsJohn Bilello, Bo Pi
Life of this patent
Estimating the term…
Abstract
Materials and Methods for stratifying disease severity and for monitoring major depressive disorder are provided.
Claims24
A method of stratifying disease severity in a subject, comprising:
- (a) providing a numerical value for each of a plurality of analytes relevant to mild, moderate, and severe states of depression, wherein each numerical value corresponds to the level of the analyte in a biological sample from the subject;
- (b) individually weighting each numerical value in a manner specific to each analyte to obtain a weighted value for each analyte;
- (c) determining a result value based on an equation that includes each weighted value;
- (d) comparing the result value to control result values obtained for a normal subject and for subjects having mild, moderate, and severe states of depression, wherein the control result values were determined in a manner comparable to that of the result value;
- and
- (e) if the result value is within a predetermined range of control values for no depression, mild depression, moderate depression, or severe depression, classifying the subject having no depression, mild depression, moderate depression, or severe depression, respectively.
3 more elements
A method for monitoring treatment of a subject diagnosed with a depressive disorder, comprising:
- (a) providing a first numerical value of each of a plurality of analytes relevant to depression, wherein each first numerical value corresponds to the level of the analyte in a first biological sample from the subject;
- (b) individually weighting each first numerical value in a manner specific to each analyte to obtain a first weighted value for each analyte;
- (c) determining a first MDD score based on an equation that includes each first weighted value;
- (d) providing a second numerical value of each of the plurality of analytes, wherein each second numerical value corresponds to the level of the analyte in a second biological sample from the subject, wherein the second biological sample is obtained after treatment for the depressive disorder;
- (e) individually weighting each second numerical value in a manner specific to each analyte to obtain a second weighted value for each analyte, with the proviso that the weighting is done in a manner comparable to that in step (b);
- (f) using the equation to determine a second MDD score after treatment of the subject for the depressive disorder;
- and
- (g) comparing the first MDD score to the second MDD score and to a control MDD score or range of MDD scores determined from one or more normal subjects, and classifying the treatment as being effective if the second MDD score is closer than the first MDD score to the control MDD score, or classifying the treatment as not being effective if the second MDD score is not closer than the first MDD score to the control MDD score.
5 more elements
A method for monitoring treatment of a subject diagnosed with a depressive disorder, comprising:
- (a) providing a first numerical value of each of a plurality of analytes relevant to depression, wherein each first numerical value corresponds to the level of the analyte in a first biological sample from the subject;
- (b) providing a second numerical value of each of the plurality of analytes, wherein each second numerical value corresponds to the level of the analyte in a second biological sample from the subject, wherein the second biological sample is obtained after treatment for the depressive disorder;
- (c) individually weighting the first and second numerical values in a manner specific to each analyte to obtain a weighted value for each analyte;
- (d) determining a monitoring score based on an equation that includes the weighted numerical values;
- and
- (e) comparing the monitoring score to a control monitoring score, and classifying the treatment as being effective if the monitoring score is greater than or equal to the control monitoring score, or classifying the treatment as not being effective if the monitoring score is less than the control monitoring score.
3 more elements
Dependencies are inferred from the claim text.